Evidence map›Paper›PMID 26286107›Full record

ArticleThe European journal of neuroscience2015

A novel dopamine transporter transgenic mouse line for identification and purification of midbrain dopaminergic neurons reveals midbrain heterogeneity.

Mia Apuschkin, Sara Stilling, Troels Rahbek-Clemmensen, Gunnar Sørensen, Guillaume Fortin, Freja Herborg Hansen, Jacob Eriksen, Louis-Eric Trudeau, Kristoffer Egerod, Ulrik Gether and 1 more

Open access · greenAbstract read
In one paragraph

Article in The European journal of neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. An unsuspected role for organic cation transporter 3 in the actions of amphetamine.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Mia ApuschkinDepartment of Neuroscience and Pharmacology, Molecular Neuropharmacology and Genetics Laboratory, Lundbeck Foundation Center for Biomembranes in Nanomedicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Sara StillingDepartment of Neuroscience and Pharmacology, Molecular Neuropharmacology and Genetics Laboratory, Lundbeck Foundation Center for Biomembranes in Nanomedicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Troels Rahbek-ClemmensenDepartment of Neuroscience and Pharmacology, Molecular Neuropharmacology and Genetics Laboratory, Lundbeck Foundation Center for Biomembranes in Nanomedicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Gunnar SørensenDepartment of Neuroscience and Pharmacology, Molecular Neuropharmacology and Genetics Laboratory, Lundbeck Foundation Center for Biomembranes in Nanomedicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Guillaume FortinDepartment of Pharmacology and Groupe de Recherche sur le Système Nerveux Central, Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada.
Freja Herborg HansenDepartment of Neuroscience and Pharmacology, Molecular Neuropharmacology and Genetics Laboratory, Lundbeck Foundation Center for Biomembranes in Nanomedicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Jacob EriksenDepartment of Neuroscience and Pharmacology, Molecular Neuropharmacology and Genetics Laboratory, Lundbeck Foundation Center for Biomembranes in Nanomedicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Louis-Eric TrudeauDepartment of Pharmacology and Groupe de Recherche sur le Système Nerveux Central, Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada.
Kristoffer EgerodDepartment of Neuroscience and Pharmacology, Molecular Pharmacology Laboratory, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Ulrik GetherDepartment of Neuroscience and Pharmacology, Molecular Neuropharmacology and Genetics Laboratory, Lundbeck Foundation Center for Biomembranes in Nanomedicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Mattias RickhagDepartment of Neuroscience and Pharmacology, Molecular Neuropharmacology and Genetics Laboratory, Lundbeck Foundation Center for Biomembranes in Nanomedicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
University of Copenhagen · DKLundbeck Foundation · DKUniversité de Montréal · CA

Funding

STRUCTURE/FUNCTION OF THE HUMAN DOPAMINE TRANSPORTERP01DA012408 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI WEINSTEIN, HAREL · 1999 to 2015
$14.2M
Canadian Institutes of Health ResearchNIDA NIH HHS P01 DA012408NIDA NIH HHS P01 DA12408
6 · The paper itself

Abstract

Midbrain dopaminergic (DAergic) neurons are a heterogeneous cell group, composed of functionally distinct cell populations projecting to the basal ganglia, prefrontal cortex and limbic system. Despite their functional significance, the midbrain population of DAergic neurons is sparse, constituting only 20 000-30 000 neurons in mice, and development of novel tools to identify these cells is warranted. Here, a bacterial artificial chromosome mouse line [Dat1-enhanced green fluorescent protein (eGFP)] from the Gene Expression Nervous System Atlas (GENSAT) that expresses eGFP under control of the dopamine transporter (DAT) promoter was characterized. Confocal microscopy analysis of brain sections showed strong eGFP signal reporter in midbrain regions and striatal terminals that co-localized with the DAergic markers DAT and tyrosine hydroxylase (TH). Thorough quantification of co-localization of the eGFP reporter signal with DAT and TH in the ventral midbrain showed that a vast majority of eGFP-expressing neurons are DAergic. Importantly, expression profiles also revealed DAergic heterogeneity when comparing substantia nigra and ventral tegmental area. Dat1-eGFP mice showed neither change in synaptosomal DA uptake nor altered levels of DAT and TH in both striatum and midbrain. No behavioural difference between Dat1-eGFP and wild-type was found, suggesting that the strain is not aberrant. Finally, cell populations highly enriched in DAergic neurons can be obtained from postnatal mice by fluorescence-activated cell sorting and the sorted neurons can be cultured in vitro. The current investigation demonstrates that eGFP expression in this mouse line is selective for DAergic neurons, suggesting that the Dat1-eGFP mouse strain constitutes a promising tool for delineating new aspects of DA biology.

Indexed as

AnimalsBehavior, AnimalDopamine Plasma Membrane Transport ProteinsDopaminergic NeuronsFemaleFlow CytometryGreen Fluorescent ProteinsMaleMiceMice, Inbred C57BLMice, TransgenicSynaptosomesTyrosine 3-MonooxygenaseVentral Tegmental AreaDopamine Plasma Membrane Transport Proteinsenhanced green fluorescent proteinGreen Fluorescent ProteinsSlc6a3 protein, mouseTyrosine 3-Monooxygenasedopaminergic culturesenhanced green fluorescent proteinfluorescence-activated cell sortingtransgenic miceventral midbrain

Identifiers

PMID26286107
PMCPMC4789538
OpenAlexW2135961916

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.